Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer
Carcinogenesis · 2023
DOI: 10.1093/carcin/bgad028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2023. Verfasst von Qing Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, RNA, Long Noncoding, MicroRNAs. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Natural Science Foundation of China, Scientific Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Lung cancer is the leading cause of cancer-related deaths worldwide. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) showed great therapeutic efficacy for non-small cell lung cancer (NSCLC) patients. However, acquired resistance severely limits the clinical application and efficacy of EGFR-TKIs. In the current study, we found that solamargine (SM), a natural alkaloid derived from the fruit of Lycium tomato lobelia, has been found to inhibit the progression of NSCLC and enhance the anticancer effect of EGFR-TKIs. In brief, SM significantly inhibited the cell viability of NSCLC cells and enhanced the anticancer effect of gefitinib (GFTN) and erlotinib (ERL). Mechanistically, SM decreased the expression of MALAT1 and induced miR-141-3p, whereas reduced SP1 protein levels. Interestingly, both MALAT1 and Sp1 have classical and conservative binding sites of miR-141-3p in their 3ʹ-UTR regions. Silence of MALAT1 and overexpression of miR-141-3p both decreased the protein expression of Sp1. Subsequently, promoter activity and protein expression of IGFBP1 were upregulated by SM, which was not observed in cells with SP1 overexpression. Moreover, the inhibitory effect of SM on cell growth was significantly blocked by knockdown of IGFBP1 expression. More importantly, the combination of SM and GFTN synergistically inhibited the progression of lung cancer. Similar results were observed in experiments in vivo. Finally, the clinical relevance of MALAT1, Sp1 and IGFBP1 was further validated using bioinformatics analysis. Taken together, we confirmed that SM significantly enhanced the anticancer effect of EGFR-TKIs by regulating the MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway. This study unravels a novel mechanism and suggests a new potential NSCLC-associated therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Gu…
- Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou, Guangdong 510120, PR Chi…
- Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, Guangdong 510120, PR China.
- Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510120, PR China.
ORCID-Profile: Qing Tang, Sumei Wang
Förderung
- Natural Science Foundation of China
- Scientific Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine
- Natural Science Foundation of Guangdong Province
- Guangzhou Science and Technology Plan Project
- Scientific Research Project in Universities of Guangdong Provincial Department of Education
- Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome
- Bajian Talents of Guangdong Provincial Hospital of Chinese Medicine
- Key project of State Key Laboratory of Dampness Syndrome of Chinese Medicine
Zitieren
APA
Tang, Q., Zhou, Q., Li, J., Yang, X., Wang, R., Wang, X., Xu, M., Han, L., Wu, W., & Wang, S. (2023). Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgad028
Vancouver
Tang Q, Zhou Q, Li J, Yang X, Wang R, Wang X, et al. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer. Carcinogenesis. 2023. doi:10.1093/carcin/bgad028
BibTeX
@article{Tang2023,
author = {Tang, Qing and Zhou, Qichun and Li, Jing and Yang, Xiaobing and Wang, Rui and Wang, Xi and Xu, Mengfei and Han, Ling and Wu, Wanyin and Wang, Sumei},
title = {Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer},
journal = {Carcinogenesis},
year = {2023},
doi = {10.1093/carcin/bgad028}
}
EUVIMED